Is Compounded Tirzepatide Legal and Safe? FDA Rules and What Changed in 2026
It depends on the pharmacy and the prescription. Tirzepatide's shortage ended in October 2024, the broad shortage pathway for compounding closed in early 2025, and FDA has not reviewed compounded tirzepatide for safety or quality.
Programs still sell it. Here is what each charges, what the law requires and what to check before you pay.
By GLP-1 Picks, an independent comparison publication. Sources linked below. Our editorial policy.
Summarize this article with

What tirzepatide costs at each program we track
Compare each published quote with its payment terms. The rows include medication prices, care fees and prepaid equivalents. Select a name or price for that plan.
- Collective Compounded Tirzepatide$69/mo
Compounded tirzepatide · billed monthly
$69 billed monthly for medication at any dose, plus required membership free for 21 days then $199/year. Twelve medication payments plus one membership: $1,027 before any technology transaction fee, which the terms do not price. Not a verified complete bill.
Full terms for Collective
We checked this price on Oct 17, 2026.
Full review and sources - Nu Image Medical Compounded tirzepatide injection, six-month plan$89/mo
Compounded tirzepatide · 6-mo prepay
Provider-confirmed starting rate: $534 paid upfront for six months, plus shipping from $15/order. Three-month plan: $199/mo ($597 upfront); month-to-month: $299. Compounded medications are not FDA-approved. Prescription required; confirm dose, other fees and renewal.
Full terms for Nu Image Medical
We checked this price on Oct 11, 2026.
Full review and sources - Gala Compounded Tirzepatide (yearly plan)$99/mo
Compounded tirzepatide · yearly plan
From $99/mo for compounded tirzepatide on the annual plan, billed once a year. Your price depends on your state, dose and plan. Confirm the full charge and renewal at checkout.
Full terms for Gala
We checked this price on Nov 15, 2026.
Full review and sources - MEDVi(affiliate link) Zepbound membership$99 (affiliate link)
Zepbound
Monthly membership shown on the Zepbound card. The medication cost is added on top and is not published, and availability is subject to change
Full terms for MEDVi
Monthly membership shown on the Zepbound card. The medication cost is added on top and is not published, and availability is subject to change (verified 2026-09-03)
We checked this price on Nov 3, 2026.
Full review and sourcesThis content was researched and written with AI assistance. MEDVi referral links are affiliate links: we may earn a commission if you sign up. This is independent information, not medical advice or a clinical review.
- SkinnyRx Compounded Tirzepatide (injectable)$99/mo
Compounded tirzepatide · first month
Once-weekly tirzepatide injection, a GLP-1 and GIP dual agonist, quoted at $99 for the first month on its product page.
Full terms for SkinnyRx
We checked this price on Sep 26, 2026.
Full review and sources - Maximus Compounded Tirzepatide (12-month plan)$99.99/mo
Compounded tirzepatide · 12-mo prepay
Product-page monthly equivalent; the full twelve-month term is paid upfront. Shipping and clinical oversight included, required labs billed separately. Confirm the bill: the help center lists a different schedule.
Full terms for Maximus
We checked this price on Oct 24, 2026.
Full review and sources - SnagRx Compounded Tirzepatide (12-month plan)$119/mo
Compounded tirzepatide · 12-mo plan
Billed as $1,428 once; the rate the homepage leads with
Full terms for SnagRx
We checked this price on Oct 1, 2026.
Full review and sources - Trimi Health Compounded Tirzepatide, Annual Plan$125/mo
Compounded tirzepatide · annual prepay
$125 monthly equivalent with $1,500 prepaid for twelve months. Does not auto-renew; a fresh provider check-in is required. Refunds remain subject to the published policy.
Full terms for Trimi Health
We checked this price on Oct 20, 2026.
Full review and sources
Quotes are ordered by their listed amount. Compare what each price includes and when payment is due. Some of these programs pay us a commission. That never changes a price or the order.
In this article
- 01Is compounded tirzepatide legal in 2026?
- 02Is compounded tirzepatide safe?
- 03What is compounded tirzepatide?
- 04How much does compounded tirzepatide cost?
- 05Compounded or brand-name tirzepatide: which should you choose?
- 06What could further restrict compounded tirzepatide?
- 07How to start compounded tirzepatide
- 08Frequently Asked Questions
- 09Sources
Tirzepatide's FDA shortage status was resolved on October 2, 2024, and the agency's shortage-based enforcement-discretion periods ended in early 2025.
Telehealth services still advertise compounded tirzepatide, including EverPrime compounded tirzepatide plans, Shed at $299/month, and Sprout Health compounded tirzepatide at $199 every 4 weeks (2025 FDA warning for misleading compounded-drug marketing).
Those are advertised commercial terms, not a determination that a particular prescription or batch satisfies federal or state compounding law.
Brand-name Zepbound is FDA-approved and listed at $299-$449/month for certain LillyDirect vial doses, with a higher retail list price.
A pharmacist or attorney familiar with the prescription and pharmacy must evaluate the applicable section 503A or 503B conditions.
Quick answer by situation:
- •Compounded tirzepatide plan terms: EverPrime compounded tirzepatide plans; compare total commitment, billing schedule and renewal before choosing
- •Fastest compounded tirzepatide delivery: Shed $299/mo, 2-3 day shipping
- •FDA-approved brand cash path: LillyDirect Zepbound from $299/mo for eligible vial doses
- •Compare care and payment terms: Sprout Health compounded tirzepatide is $199 every 4 weeks or $1,788 paid annually (2025 FDA warning for misleading compounded-drug marketing), with clinician review and shipping included. Its current public offer does not establish superior care or an expected weight-loss outcome.
- •Monthly or prepaid injection plans: bmiMD lists compounded tirzepatide at $249 month to month or $179/month with $2,148 paid up front for twelve months; clinician visits and shipping are included (standard plan prices checked September 12, 2026)
- •Full legal framework: Brand vs compounded GLP-1 guide
This guide covers the post-shortage FDA framework, the distinct conditions in sections 503A and 503B, the FDA's concerns about unapproved GLP-1 products, and the public records a reader can review in our warning and transparency checker.
The checker does not certify legal compliance, pharmacy quality, or medication safety.
Check the rules before you choose a program
Ask any program which medication you'd get, which pharmacy makes it and who writes the prescription. The FDA alerts page shows what has changed.
Read FDA alerts and compounding updates →Is compounded tirzepatide legal in 2026?
There is no single yes or no for every compounded tirzepatide prescription. Tirzepatide's shortage was resolved in October 2024, so the broad shortage-based enforcement pathway ended in early 2025.
Whether a specific preparation may be compounded now depends on the facts and on all applicable federal and state conditions, including the distinct rules for a section 503A pharmacy or a section 503B outsourcing facility.
The FDA shortage list: FDA resolved the tirzepatide shortage on October 2, 2024, and later ended temporary enforcement discretion for shortage-based copies.
Outside that pathway, section 503A's patient-specific requirements and its 'essentially a copy' limits, and section 503B's separate requirements, require a case-specific analysis; a prescriber-documented clinically significant difference can matter under section 503A, but it is not an automatic safe harbor for every advertised program.
On April 30, 2026, FDA proposed excluding tirzepatide from the 503B bulk drug substances list.
The comment period closed July 30, 2026, but a proposal is not a final rule. See our brand vs compounded guide for the framework.
| Pharmacy Type | Regulation | What It Means For You |
|---|---|---|
| 503A Pharmacy | State-regulated, patient-specific prescriptions | Your prescription is filled individually for you. Must have a valid patient-prescriber relationship. Some states have additional restrictions. |
| 503B Outsourcing Facility | Registered with FDA and subject to section 503B conditions | Registration is a public record, not FDA approval of each product or a guarantee of safety. Review inspection and quality records separately. |
FDA enforcement records cover different allegations, including marketing, labeling, and manufacturing issues; a marketing warning is not proof that a medication was unsafe, and the absence of a letter is not proof of compliance.
Ask the telehealth company to name the dispensing pharmacy, then check the applicable state license or FDA outsourcing-facility registration and any inspection records.
Our warning and transparency checker is a non-exhaustive public-record aid, not a certification.
Is compounded tirzepatide safe?
Brand-name Zepbound safety and efficacy findings cannot be assigned to a compounded product. FDA has not reviewed compounded tirzepatide products for identity, concentration, sterility, safety, or effectiveness.
Risk therefore includes both the expected class risks a prescriber should discuss and product-specific uncertainty about what was prepared and how it was labeled.
- •Potency accuracy: Brand-name Zepbound is manufactured under strict cGMP (current Good Manufacturing Practice) with precise dosing. Compounded versions may have slight variations in potency depending on the pharmacy's quality controls.
- •Sterility: Injectable medications must be sterile. FDA-registered 503B facilities follow stricter sterility standards than many 503A pharmacies. Contamination risk is the most serious safety concern with compounded injectables.
- •Inactive ingredients: Compounded formulations may use different buffers, preservatives, or solvents than the brand-name product. These can affect tolerability and injection site reactions.
- •Different oversight: Adverse events involving compounded drugs can be reported to FDA, but compounded products do not undergo the same premarket review and manufacturer pharmacovigilance system as an approved brand.
If a prescriber recommends a compounded product, ask for the dispensing pharmacy's legal name before paying, verify the relevant state license or FDA outsourcing-facility registration, review inspection or disciplinary records, and confirm the exact concentration and syringe units with the pharmacist.
Registration alone does not establish product safety.
Strut Health received FDA warning letter MARCS-CMS 721448, dated February 20, 2026, concerning marketing that implied FDA approval.
The letter concerns marketing claims, not a finding that the medication was unsafe, and no close-out letter has been posted.
What is compounded tirzepatide?
Products marketed as compounded tirzepatide are pharmacy-prepared formulations intended to contain tirzepatide rather than Eli Lilly-manufactured Zepbound or Mounjaro.
FDA has not reviewed those finished products for identity, strength, quality, safety, or effectiveness, so they should not be described as the same drug, an approved generic, or clinically equivalent. Advertised forms include:
- •Pre-mixed injectable solution: Ready to inject, similar to using a brand-name pen. Most telehealth providers ship this format for convenience.
- •Lyophilized (freeze-dried) powder: Comes as a powder in a vial that you reconstitute with bacteriostatic water before injecting. Less common through telehealth, more common from direct compounding pharmacies.
- •Oral dissolvable gum: A compounded tirzepatide gum that dissolves in the mouth, requiring no injection. No longer offered by Embody, which discontinued it. Compounded oral dissolving tirzepatide tablets remain available from some programs and are a non-injectable tirzepatide option for needle-phobic patients.
The key difference from brand-name is not merely packaging: compounded tirzepatide is not FDA-approved as a finished product.
Concentration, formulation, inactive ingredients, container, instructions, and manufacturing controls may differ, and FDA has not established equivalence to an Eli Lilly product.
How much does compounded tirzepatide cost?
These are advertised compounded tirzepatide program prices, not insurance copays or guaranteed checkout totals. Compare the exact formulation, dose, renewal charge and required care fees.
An introductory amount is not the recurring cost; open the provider review for dated pricing evidence and limitations:
| Provider | Monthly Cost | Score | Key Details |
|---|---|---|---|
| EverPrime compounded tirzepatide plans | Confirm total commitment and billing schedule | 9.4/10 | Plan-dependent terms; confirm the prescribed formulation |
| Shed | $299/mo | 7.9/10 | Fastest delivery (2-3 days). Streamlined onboarding. 45 states. |
| Willow | $399 to $549/mo | 7.6/10, active alert: stock-photo testimonial | Compounded tirzepatide injection with included care and shipping. Price varies by listed dose; not a brand-name program. |
| Embody | from $129/mo on a selected plan | 7.6/10, active alert: delivery complaints | Compounded GLP-1 + GIP injection from $129 month-to-month, $99/mo equivalent in a yearly-plan sale advertised through December 1, 2026 ($1,188 prepaid). Includes metabolic report + 24/7 support. |
| Sprout Health (2025 FDA warning for misleading compounded-drug marketing) | $199 every 4 weeks | 7.8/10, active alerts: FDA warning, delivery complaints | Compounded tirzepatide shortest plan; annual option is $1,788 upfront ($149/month equivalent). See our review for reputation concerns. |
For brand-name comparison: Zepbound via LillyDirect costs $299 to $449/month self-pay, or $1,086/month at retail pharmacy list price. With insurance and a savings card, brand-name can be as low as $25/month.
See our full tirzepatide cost breakdown for all pricing options.
Needle-phobic? SynergyRx lists compounded oral dissolving tablets for both semaglutide and tirzepatide.
Embody, by contrast, is injection-only since discontinuing its oral gum; its GLP-1 + GIP is $129 month-to-month. Our Embody tirzepatide reviews page walks through every tier before you sign up. Breeze Meds lists compounded oral semaglutide from $299/mo and oral tirzepatide from $399/mo.
Its complete payment and recurring-charge terms remain unverified. Ask for the full quote and renewal terms in writing; do not assume a first order has no further commitment.
Want medication and care in one program price? Willow's compounded tirzepatide injection starts at $399/mo, rising to $499, $524 or $549 at higher listed dose tiers.
Its supplied-medication program includes care and shipping, but it is not a single flat rate at every dose.
The current Willow price schedule, checked September 26, 2026, separates injection and tablet prices.
Confirm the prescribed formulation and total before comparing it with another provider.
For Bodybuilding Health+, our September 3 price check found different totals for the same supply on its bundle selector and product pages. The selected plan's complete bill remains unverified here.
Confirm the medication, supply length, renewal terms and total including care and shipping in writing before comparing.
See the full ranked list of all tirzepatide providers at our cheapest tirzepatide comparison, or take our match quiz to find the right provider for you.
Compounded or brand-name tirzepatide: which should you choose?
| Factor | Compounded | Brand-Name (Zepbound) |
|---|---|---|
| Cost without insurance | $149 to $300/mo | $299 to $1,086/mo |
| Cost with insurance + savings card | Rarely covered | As low as $25/mo |
| FDA approved | No | Yes |
| Medicare GLP-1 Bridge, if eligible | Not included | Zepbound KwikPen only, $50/month after authorization |
| Manufacturing quality | Varies by pharmacy | Eli Lilly cGMP facilities |
| Regulatory status | Shortage pathway ended; a specific preparation must satisfy applicable 503A or 503B and state-law conditions | FDA-approved product with labeled indications and conditions of use |
| Delivery format | Vials (self-inject with syringe) | Auto-injector pen (easier) |
| Clinical evidence | No product-specific pivotal trial identified; branded SURMOUNT results do not establish compounded outcomes | Zepbound was directly studied in SURMOUNT trials |
Choose compounded if: You're paying cash without insurance, want the lowest monthly cost, and are comfortable with the regulatory uncertainty and self-injection with vials.
Choose brand-name if: You have insurance that covers Zepbound, qualify for Medicare coverage (July 2026), want the convenience of an auto-injector pen, or prefer the certainty of an FDA-approved product.
For a broader comparison including semaglutide options, read our brand-name vs compounded GLP-1 guide and semaglutide vs tirzepatide comparison.
What could further restrict compounded tirzepatide?
The shortage-based pathway has closed: FDA resolved the tirzepatide shortage in October 2024 and ended its temporary enforcement-discretion periods in early 2025.
A compounded preparation offered after those dates must be evaluated under all applicable section 503A or 503B and state-law conditions; this article cannot determine that from a provider's storefront.
FDA's April 30, 2026 proposal would also exclude tirzepatide from the 503B bulk drug substances list.
The comment period closed July 30, 2026, but the proposal is not final and its market effects should not be presented as settled.
If 503B access tightens further, your options would be:
- •Discuss brand-name Zepbound with a clinician. Willow's current menu is compounded, not brand-name Zepbound. The Zepbound guide covers separate brand-name access routes. A new provider must assess the prescription and supply; no treatment gap can be ruled out in advance.
- •Note on compounded semaglutide: FDA resolved that shortage on February 21, 2025 and later ended its shortage-based enforcement discretion. That is different from declaring every patient-specific compounded prescription illegal. See our post-shortage semaglutide guide for the applicable distinctions.
- •Check the Medicare route. The separate Bridge includes Zepbound KwikPen only at $50 per monthly supply if eligible and authorized. It does not cover compounded tirzepatide, single-dose Zepbound pens or vials. Medicare's covered products; our Medicare guide separates Bridge from ordinary Part D.
- •Ask about an oral brand: Foundayo (orforglipron) is an FDA-approved oral GLP-1 pill at $149-$349/month through LillyDirect depending on dose and refill timing.
How to start compounded tirzepatide
- •Step 1: Choose a provider. Compare EverPrime compounded tirzepatide plans, Shed ($299/mo), or Sprout Health (2025 FDA warning for misleading compounded-drug marketing) (compounded tirzepatide at $199 every 4 weeks) to compare its clinician-review and billing terms. See all options ranked at cheapest tirzepatide.
- •Step 2: Complete the medical questionnaire. Most providers use an online questionnaire, with no video call. You'll provide your medical history, current medications, and weight loss goals.
- •Step 3: Provider review and prescription. A licensed provider reviews your profile and prescribes tirzepatide if appropriate. Typical approval time: 24-72 hours.
- •Step 4: Confirm fulfillment and shipping. Ask the provider for the dispensing pharmacy, processing estimate, shipping charge and transit time after approval. A delivery date counted from signup is not established for Shed; confirm the timetable for your prescription before relying on it.
- •Step 5: Verify the compounded instructions before dosing. Concentrations, containers, and syringe-unit directions can vary. Confirm the prescribed milligrams, the vial's mg/mL concentration, and the corresponding syringe units with the prescriber or dispensing pharmacist. Do not assume the Zepbound pen schedule applies to a compounded formulation.
Not sure if tirzepatide is right for you? Take our eligibility checker to see if you qualify, or use the match quiz to compare providers based on your specific situation.
Frequently Asked Questions
Is compounded tirzepatide the same as Zepbound?
No. A product marketed as compounded tirzepatide is not FDA-approved as Zepbound, is not an approved generic, and has not been established by FDA as identical or equivalent.
Its formulation, concentration, inactive ingredients, container, instructions, and quality controls may differ.
What is the cheapest compounded tirzepatide?
The visible floor depends on what is being compared. Gala lists compounded tirzepatide from $99/month equivalent on an annual plan, billed once a year; EverPrime compounded tirzepatide plans have commitment-specific billing terms; Shed advertises $299/month.
Those are different products and billing terms, not a uniform all-in ranking. See the qualifiers in our tirzepatide price comparison.
Can my doctor prescribe compounded tirzepatide?
A licensed prescriber may determine that a patient-specific compounded preparation is appropriate, but the prescription and pharmacy still must satisfy applicable federal and state requirements.
Ask the prescriber to document why the compounded formulation is needed and ask the dispensing pharmacy which section 503A or 503B conditions it relies on; telehealth convenience does not establish compliance.
How long will compounded tirzepatide be available?
No one can reliably promise availability. Tirzepatide's shortage was resolved in October 2024 and shortage-based enforcement discretion ended in early 2025.
Any continued compounding depends on the specific prescription, pharmacy, substance, and applicable 503A or 503B and state-law conditions.
FDA's April 2026 503B bulk-list proposal is pending, with no stated date for a final decision. Monitor our safety center for sourced updates.
Should I choose compounded tirzepatide or compounded semaglutide?
That choice requires a prescriber to assess your medical history, the exact formulation, and whether a patient-specific compounded preparation is appropriate and lawful.
Both products are unapproved; branded Zepbound and Wegovy trial results cannot be used as efficacy estimates for a compounded product.
Read our semaglutide vs tirzepatide comparison for evidence about the FDA-approved brands, and our post-shortage semaglutide guide for regulatory context.
Sources
- FDA Drug Shortage Database, Tirzepatide, U.S. Food and Drug Administration
- SURMOUNT-1: Tirzepatide for Treatment of Obesity, New England Journal of Medicine, 2022
- FDA Compounding Quality Act, Section 503A and 503B, FDA
- Compounded Tirzepatide: Legal and Safety Overview, GLP-1 After Denial, 2026
- Zepbound Prescribing Information, Eli Lilly / FDA Label
Medical disclaimer: This article is general information, not medical advice. Talk to a licensed clinician before you start, stop or change any medication. Prices and rules can change after the date we checked them.
Affiliate disclosure: Some links in this article are affiliate links. If you join a program through one, we may earn a commission at no extra cost to you.
Medicare & GLP-1
Medicare GLP-1 Coverage Guide
On Medicare? From July 1, 2026, the Medicare GLP-1 Bridge sets a $50 monthly copay for Wegovy, Zepbound and Foundayo. Our guide explains who qualifies and what it covers.
Read the Medicare guide →Related Reading
Keep exploring this topic
What the doctors say
Quotes from named doctors and medical bodies, each linked to where they said it. We did not ask for them, and they do not endorse any provider.
“While compounding can play an appropriate role when used to meet the specific needs of an individual patient, the large-scale production and marketing of compounded versions of these medicines raises serious safety risks when products have not undergone the rigorous scientific and regulatory review required for FDA-approved therapies.”
“It's not just filling out a form online and then having some random healthcare provider sign off on it. There are concerns with some of these online programs that there's not a proper evaluation, there's not a baseline, and there's not proper supervision.”
“Compounded drugs can be important for overcoming shortages or meeting unique patient needs, but compounders should not try to compound drugs in a way that circumvents FDA's approval process.”
Quotes are general medical commentary about GLP-1 medications, independently sourced and not solicited by GLP-1 Picks. They are not an endorsement of any provider, our provider scores are set solely by our published methodology.




